UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/600/0.1/17.12.25 | Market Closed - Börse Stuttgart 11:48:11 24/05/2024 pm IST | ||
| 3.29 EUR | +6.82% |
|
| Current month | +106.92% | ||
| 1 month | +76.88% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24/24/24 | 3.29 | +6.82% |
| 23/24/23 | 3.08 | +2.33% |
| 22/24/22 | 3.01 | +5.99% |
| 21/24/21 | 2.84 | -4.05% |
| 20/24/20 | 2.96 | +2.07% |
Delayed Quote Börse Stuttgart
Last update May 24, 2024 at 11:48 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HD1H59 |
| ISIN | DE000HD1H598 |
| Date issued | 28/12/2023 |
| Strike | 600 $ |
| Maturity | 17/12/2025 (572 Days) |
| Parity | 10 : 1 |
| Emission price | 2.64 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.31 € |
|---|---|
| Lowest since issue | 1.55 € |
| Spread | 0.03 € |
| Spread % | 0.90% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
457
USD
Average target price
462.8
USD
Spread / Average Target
+1.28%
- Stock Market
- Warrants
- Warrant
